ClinicalTrials.gg
CompletedNCT03658161CASCADEUpdated Sep 23, 2019

Communicating About Sexual Concerns and Dysfunction Effectively (CASCADE) Program

An interventional study of Communicating About Sexual Concerns and Dysfunction Effectively in Cancer, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Duke University · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2017, registered Aug 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients with cancer suffer many devastating side effects; one that is understudied but vital to quality of life is the effect of cancer and its treatments on patients' sexual functioning and satisfaction. The long-term goal of this work is to improve the care of patients with cancer who are experiencing difficulties with sexual function and satisfaction. As a necessary first step, providers must be skilled in eliciting patients' concerns about sexual health and addressing them appropriately. However, prior studies have found that (1) oncology providers are reluctant to discuss sexual issues with their patients, (2) patients report that needed conversations about their sexual concerns do not occur, and (3) patients want to discuss sexual health with their provider. Thus, the goal of the present study is to develop and test a brief intervention to improve oncology provider's skills in addressing patients' concerns regarding sexual function-the Communicating about Sexual Concerns and Dysfunction Effectively (CASCADE) Program.

To aid in development of the intervention, focus groups will be held and target 9 distinct populations of cancer survivors: 1) Breast; 2) Gynecologic; 3) Prostate; 4) males with gastrointestinal malignancies; 5) females with gastrointestinal malignancies; 6) males with brain tumors; 7) females with brain tumors; 8) LGBTQ individuals who identify as male; 9) LGBTQ individuals who identify as female. Maximum accrual for this phase will be 90 patients for 9 focus groups, or a maximum of 10 patients per group. Groups will last approximately 75 minutes and be audio recorded. Participants will also complete self-report measures which as about their sexual functioning, emotional wellbeing, physical functioning and utilization of services offered through the Duke Cancer Institute.

The intervention will then be pilot tested with up to 10 providers to assess feasibility and acceptability of the protocol. Specifically, the coaching intervention will include two parts: 1) initial coaching session with one of the study PIs, Dr. Kathryn Pollak; and 2) follow-up appointment with Dr. Pollak to check in on use of the intervention strategies. Providers will also complete self-report assessments prior to initiating CASCADE and upon completion of CASCADE. Clinic staff will let patients know that the clinic is participating in a research study about how to improve communication between patients and providers and provide patients of participating providers with an anonymous survey to complete following their clinic visit. The paper surveys will be given to all patients of the participating provider being seen in the clinic approximately 5 days prior to the coaching intervention session and 5 days following the intervention (e.g., second session with Dr. Pollak).

Descriptive statistics (e.g., means, standard deviations) will be used to characterize the experience of patients participating in focus groups with regard to their sexual functioning, emotional distress (i.e., symptoms of anxiety and depression), and physical functioning. Qualitative methods will also be used to analyze the focus groups.

Feasibility of CASCADE will be assessed by examining providers' accrual, attrition, and adherence. To determine acceptability, providers will be asked how useful the intervention was, whether the intervention will change their clinical practice, and whether they would recommend the program to a colleague. Simple t-tests will be used to examine changes in outcomes of interest (e.g., confidence, barriers, etc.) from pre- to post-intervention. Basic descriptive statistics (e.g., means, standard deviations) will be used to characterize patients' experiences during the interaction.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

9,616 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.

This study's enrollment of 37 is below the median of 50 across 7,429 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Duke University is the lead sponsor of 2,058 studies on the registry; 274 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 165 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients for Focus Groups: Patients treated at the Duke Cancer Institute will be recruited to participate. Patients who self-refer to the study will also be recruited to participate, and eligibility will be verified after completing informed consent. All participants will meet the following inclusion criteria: a) aged 18 years or older; b) able to speak and understand English; and c) diagnosis of breast, prostate, gynecologic, gastrointestinal, or brain cancer and treated at the Duke Cancer Institute. Patients participating in one of the two LGBTQ groups (i.e., LGBTQ individuals who identify as male; LGBTQ individuals who identify as female) must self-identify as gay, lesbian, bisexual, transgender, or queer.
  • Providers: We will recruit a total of 8 providers from the Duke Cancer Institute, including 2 from each type of cancer that we are targeting (breast, gynecologic, colorectal, and prostate). Within each cancer site, we will recruit one physician and one physician-extender (physician assistant, nurse practitioner, or nurse) to represent the range of provider types. Eligible providers will be currently treating patients in one of the above listed disease groups at the Duke Cancer Institute.
  • Patients recruited for CASCADE: Patients treated at the Duke Cancer Institute will be recruited to complete the anonymous survey. All participants will meet the following inclusion criteria: a) aged 18 years or older; b) able to speak and understand English; and c) diagnosis of breast, prostate, gynecologic, or gastrointestinal cancer and treated at the Duke Cancer Institute.

Exclusion criteria

Exclusion Criteria:

  • Patients for Focus Groups: Patients who meet any of the following criteria will be excluded: a) \< 18 years old; b) cognitive or hearing impairment that is documented in the medical record, or c) unable to provide meaningful consent (i.e., severe cognitive impairment such that descriptions of the research are not clearly understood).
  • Providers: Providers who treat cancers other than breast, gynecologic, colorectal, and prostate cancers will not be eligible to participate.
  • Patients for CASCADE: Patients who meet any of the following criteria will be excluded: a) \< 18 years old; b) cognitive or hearing impairment that is documented in the medical record, or c) unable to provide meaningful consent (i.e., severe cognitive impairment such that descriptions of the research are not clearly understood).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    CASCADE

    Oncology providers will receive the CASCADE coaching intervention.

    Behavioral: Communicating About Sexual Concerns and Dysfunction Effectively

Interventions

  • BehavioralCommunicating About Sexual Concerns and Dysfunction Effectively

    The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.

    Also known as: CASCADE

06

What researchers measure

Primary outcomes

  1. PROMIS Sexual Function and Satisfaction v2 - brief profile (Sex-SF)

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual Function and Satisfaction scale asks participants to provide information about their sexual functioning and satisfaction over the last 30 days. Separate versions of the measure will be used for males and females to address gender-specific differences in sexual functioning (e.g., pain and discomfort in the clitoris or labia vs. ability to maintain an erection). The male version of the questionnaire consists of 10 items while the female version of the questionnaire consists of 14 items. Items are assessed using a 5 point scale.

    Time frame: Focus group participants will complete this measure at the time of the focus group; up to 2 hours

  2. PROMIS four-item Anxiety Scale

    The Patient-Reported Outcomes Measurement Information System (PROMIS) four-item Anxiety Scale is a self-report measure of anxiety. The measures assesses fear (I felt fearful), anxious misery (i.e., My worries overwhelm me), and hyperarousal (i.e., I found it hard to focus on anything other than my anxiety), and arousal-related somatic symptoms (i.e., I felt uneasy) over the last seven days. Each item is rated on a 5 point scale ranging from 1 "never" to 5 "always." Items are summed and converted to standardized T-scores with higher scores indicative of more symptoms of anxiety. The PROMIS Anxiety Scale has been shown to have good internal reliability and convergent validity with other well validated measures of anxiety.

    Time frame: Focus group participants will complete this measure at the time of the focus group; up to 2 hours

  3. PROMIS four-item Depression Scale

    The Patient-Reported Outcomes Measurement Information System (PROMIS) four-item Depression Scale is a self-report measure of depressive symptoms. The measures assesses presence of depressed mood (i.e., I felt depressed, I felt hopeless, I felt helpless), as well as their self-view (e.g., I felt worthless) over the last seven days. Somatic symptoms of depression are not included in the measure as they frequently overlap with comorbid physical health concerns among medical populations. Each item is rated on a 5 point scale ranging from 1 "never" to 5 "always." Items are summed and converted to standardized T-scores with higher scores indicative of more depressive symptoms. The PROMIS Depression Scale has been shown to have good internal reliability and convergent validity with other well validated measures of depression.

    Time frame: Focus group participants will complete this measure at the time of the focus group; up to 2 hours

  4. PROMIS four-item Physical Function scale

    The Patient-Reported Outcomes Measurement Information System (PROMIS) four-item Physical Function scale is a self-report measure of physical functioning. The measure assesses self-reported capability of physical activities including instrumental activities (e.g., "Are you able to run errands and shop)" and mobility (e.g. "Are you able to go up and down stairs at a normal pace"). Each item is rated on a t point scale ranging from 1 "Unable to do" to 5 "Without any difficulty." Items are summed and converted to standardized T-scores, with higher scores are indicative of better physical functioning.

    Time frame: Focus group participants will complete this measure at the time of the focus group; up to 2 hours

  5. Psychosocial services use, preferences, and perceived barriers/facilitators questionnaire

    A psychosocial services use, preferences, and perceived barriers/facilitators questionnaire will be completed by patients and partners/caregivers at each assessment. Participants will be asked to indicate (yes/no) whether they have utilized a list of available psychosocial services. Next, participants will indicate with yes/no to whether they have sought services for or would like services related a list of common concerns. Participants will complete a 10-item list of barriers to seeking services. Participants will state whether or not each has served as a barrier to seeking services. Finally, participants' preferences for various delivery methods will be assess. The final two questions are open ended and ask participants to list any other services they would be interested in pursuing that were not included on the list and to provide information about what might increase their use of services.

    Time frame: Focus group participants will complete this measure at the time of the focus group; up to 2 hours

  6. Change in confidence in talking with patients about sexuality from baseline to assessment 2

    Providers will be asked to rate their confidence in addressing patients' sexual health concerns using a 6-item measure. A sample item reads, Please rate state how confident you are that you can…"Initiate a discussion about a patient's sexual health concerns" (1= not at all confident to 5= very confident). The measure to be used in the present study has been adapted from a version used in our prior research (Pollak et al., 2007) and Baile et al., 1997.

    Time frame: Baseline and Assessment 2 (up to 1 year)

  7. Change in outcome expectancies from baseline to assessment 2

    Providers will be asked an adapted 6-item communication outcomes questionnaire (Parle et al., 1997) to assess possible outcomes of communication behaviors. A sample item reads, "Asking them about their sexual health concerns will benefit them" (1=very unlikely to 5= very likely). The measure to be used in the present study has been adapted from a version used in our prior research (Pollak et al., 2007) and Parle et al., 1997.

    Time frame: Baseline and Assessment 2 (up to 1 year)

  8. Change in comfort with sexual health discussions from baseline to assessment 2

    Providers will be asked to complete a 32-item measure of provider beliefs to assess their comfort with sexual health conversations. A sample item reads, "Providers focus on organic disease because they cannot treat the sexual health concerns" (1= strongly disagree to 5=strongly agree). The measure to be used in the present study has been adapted from a version used in our prior research (Pollak et al., 2007) and Ashworth et al., 1984.

    Time frame: Baseline and Assessment 2 (up to 1 year)

  9. Communication with providers

    Patients will be asked to complete several "yes" or "no" questions about whether their provider talked with them about exercise, smoking, sexual health, nutrition and sleep (e.g., did your provider talk to you about your sexual functioning during your clinic visit?). Patients will also be asked if they had wanted their provider to talk to them about the aforementioned areas using "yes" or "no" questions (e.g., Did you want your provider to talk to you about your sexual functioning during your clinic visit?).

    Time frame: One time patient survey (15 minutes)

  10. NCCN distress screen

    The National Comprehensive Cancer Network (NCCN) Distress Thermometer and Problem List for Patients measures distress on a scale of zero to 10, 10 being the worst. The NCCN Problem list allows patients to inform their doctor if they are having concerns in areas such as practical, family, emotional, spiritual, and physical problems. This tool makes it easier for people to talk to their doctors about the these areas that may be affected by the diagnosis, symptoms, and treatment of cancer. Patients are encouraged to complete the NCCN Distress Thermometer and Problem List for Patients as part of their routine appointment preparation.

    Time frame: One time patient survey (15 minutes)

  11. Service Utilization

    A psychosocial services use, preferences, and perceived barriers questionnaire will be completed by patients. Participants will be asked to indicate (yes/no) whether they have utilized a list of available psychosocial services. Next, participants will indicate with yes/no to whether they have sought services for or would like services related to a list of common concerns. Participants will complete a 10-item list of barriers to seeking services. Participants will state whether or not each has served as a barrier to seeking services. Finally, participants' preferences for various delivery methods will be assessed.

    Time frame: One time patient survey (15 minutes)

  12. Usefulness of the intervention

    Providers will be asked how useful the intervention was on a 1 to 5 scale (1="Not at all useful" to 5="Extremely useful").

    Time frame: Assessment 2 (up to 1 year)

  13. Likelihood the intervention would change clinical practice

    Providers will be asked the likelihood the intervention would change their clinical practice assessed on a 1 to 5 scale (1="Will not change at all" to 5="Will change a lot").

    Time frame: Assessment 2 (up to 1 year)

  14. Likelihood providers would recommend the program to a colleague

    Providers will be asked the likelihood they would recommend the program to a colleague on a 1 to 5 scale (1="Definitely would not recommend" to 5="Definitely would recommend").

    Time frame: Assessment 2 (up to 1 year)

07

Study locations

1 site
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2018, 20 months.

Of 1,358 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 71. This study's 20 months is below that.

Counting every sponsor, half of 1,404 studies reached it within 38 months; a quarter within 17 and three quarters within 71.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2018
First posted
Sep 5, 2018
StartActual
Jan 6, 2017
Primary completionActual
Sep 24, 2018
CompletionActual
Jun 25, 2019
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03658161
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Jan 6, 2017
Primary completion
Sep 24, 2018
Completion
Jun 25, 2019
Last update
Sep 23, 2019

Study contacts

Kevin P Weinfurt, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion